11β-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4645-4654

  Cooper, Mark S ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; 3ALPHA(OR 20BETA) HYDROXYSTEROID DEHYDROGENASE; CARBENOXOLONE; CORTICOSTERONE; CORTISONE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROCORTISONE; INCB 13739; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; OXIDOREDUCTASE INHIBITOR; OXYSTEROL; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; B LYMPHOCYTE; BODY FAT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COGNITIVE DEFECT; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG EFFECT; ENZYME ACTIVITY; ENZYME MECHANISM; EXPERIMENTAL MODEL; GENE DELETION; GENETIC DISORDER; HORMONAL REGULATION; HUMAN; HYPERANDROGENISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER; LYMPHOID TISSUE; MACROPHAGE; METABOLIC SYNDROME X; MOLECULAR MECHANICS; MONOCYTE; MONOGENIC DISORDER; MUSCLE TISSUE; NONHUMAN; OSTEOPOROSIS; PANCREAS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEROL METABOLISM; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VASCULARIZATION; ADIPOSE TISSUE; ANIMAL; ENZYMOLOGY; GENETICS; HYPOPHYSIS ADRENAL SYSTEM; METABOLISM; MOUSE; PHYSIOLOGY;

RODENTIA;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ANIMALS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; METABOLIC SYNDROME X; MICE; PITUITARY-ADRENAL SYSTEM;

EID: 73249141243     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1412     Document Type: Review

References (99)

1. Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS, Hewison M, Stewart PM 2004 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25:831-866
2. Shimojo M, Ricketts ML, Petrelli MD, Moradi P, Johnson GD, Bradwell AR, Hewison M, Howie AJ, Stewart PM 1997 Immunodetection of 11β-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology 138:1305-1311
3. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR 1987 Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2:821-824
4. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
5. Stewart PM, Corrie JE, Shackleton CH, Edwards CR 1988 Syndrome of apparent mineralocorticoid excess.Adefect in the cortisol-cortisone shuttle. J Clin Invest 82:340-349
6. Cooper M, Stewart PM 1998 The syndrome of apparent mineralocorticoid excess. QJM 91:453-455
7. Henschkowski J, Stuck AE, Frey BM, Gillmann G, Dick B, Frey FJ, Mohaupt MG 2008 Age-dependent decrease in 11β-hydroxysteroid dehydrogenase type 2 (11βa-HSD2) activity in hypertensive patients. Am J Hypertens 21:644-649
8. Bailey MA, Paterson JM, Hadoke PW, Wrobel N, Bellamy CO, Brownstein DG, Seckl JR, Mullins JJ 2008 A switch in the mechanism of hypertension in the syndrome of apparent mineralocorticoid excess. J Am Soc Nephrol 19:47-58
9. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM 1999 Molecular basis of human salt sensitivity: the role of the 11β-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 84:3745-3749
10. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, Strain A, Hewison M, Stewart PM 2001 Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142:1982-1989
11. Bujalska IJ, Kumar S, Stewart PM 1997 Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213
12. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC 2001 Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 142:114-120
13. Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, Rabbitt EH, Stewart PM, Buckley CD, Hewison M 2006 Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. Arthritis Res Ther 8:R108
14. Thieringer R, Le Grand CB, Carbin L, Cai TQ, Wong B, Wright SD, Hermanowski-Vosatka A 2001 11β-Hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages. J Immunol 167:30-35
15. Cai TQ, Wong B, Mundt SS, Thieringer R, Wright SD, Hermanowski-Vosatka A 2001 Induction of 11β-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J Steroid Biochem Mol Biol 77:117-122
16. Jang C, Obeyesekere VR, Alford FP, Inder WJ 2009 Skeletal muscle 11βhydroxysteroid dehydrogenase type 1 activity is upregulated following elective abdominal surgery. Eur J Endocrinol 160:249-255
17. Phillipov G, Palermo M, Shackleton CH 1996 Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 81:3855-3860
18. Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC, Connell JM 1999 Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 84:3570-3574
19. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM 2003 Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34:434-439
20. Hewitt KN, Walker EA, Stewart PM 2005 Minireview: hexose-6-phosphate dehydrogenase and redox control of 11β-hydroxysteroid dehydrogenase type 1 activity. Endocrinology 146:2539-2543
21. Dzyakanchuk AA, Balázs Z, Nashev LG, Amrein KE, Odermatt A 2009 11β-Hydroxysteroid dehydrogenase 1 reductase activity is dependent on a high ratio of NADPH/NADP(+) and is stimulated by extracellular glucose. Mol Cell Endocrinol 301:137-141
22. Atanasov AG, Nashev LG, Gelman L, Legeza B, Sack R, Portmann R, Odermatt A 2008 Direct protein-protein interaction of 11β- hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the endoplasmic reticulum lumen. Biochim Biophys Acta 1783:1536-1543
23. Lavery GG, Walker EA, Tiganescu A, Ride JP, Shackleton CH, Tomlinson JW, Connell JM, Ray DW, Biason-Lauber A, Malunowicz EM, Arlt W, Stewart PM 2008 Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 93:3827-3832
24. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ 1997 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94:14924-14929
25. Carter R, Paterson JM, Tworowska U, Stenvers DJ, Mullins JJ, Seckl JR, Holmes MC 2009 Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11ss-HSD1 is strain dependent. J Neuroendocrinol, DOI: 10.1111/j.1365-2826.2009.01899x
26. Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CH, Parker KL, White PC, Stewart PM 2006 Hexose-6-phosphate dehydrogenase knock-out mice lack 11β-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 281:6546-6551
27. Rogoff D, Ryder JW, Black K, Yan Z, Burgess SC, McMillan DR, White PC 2007 Abnormalities of glucose homeostasis and the hypothalamic-pituitary- adrenal axis in mice lacking hexose-6-phosphate dehydrogenase. Endocrinology 148:5072-5080
28. Lavery GG, Walker EA, Turan N, Rogoff D, Ryder JW, Shelton JM, Richardson JA, Falciani F, White PC, Stewart PM, Parker KL, McMillan DR 2008 Deletion of hexose-6-phosphate dehydrogenase activates the unfolded protein response pathway and induces skeletal myopathy. J Biol Chem 283:8453-8461
29. Catterall WA 1991 Excitation-contraction coupling in vertebrate skeletal muscle: a tale of two calcium channels. Cell 64:871-874
30. Van Schaftingen E, Gerin I 2002 The glucose-6-phosphatase system. Biochem J 362:513-532
31. Walker EA, Ahmed A, Lavery GG, Tomlinson JW, Kim SY, Cooper MS, Ride JP, Hughes BA, Shackleton CH, McKiernan P, Elias E, Chou JY, Stewart PM 2007 11β-Hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose-6-phosphate, provides evidence for a novel link between glucose metabolism and HPA axis function. J Biol Chem 282:27030-27036
32. Basu R, Singh R, Basu A, Johnson CM, Rizza RA 2006 Effect of nutrient ingestion on total-body and splanchnic cortisol production in humans. Diabetes 55:667-674
33. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP 2009 The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 94:2692-2701
34. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 80:3155-3159
35. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001Atransgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
36. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS 2005 Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54:1023-1031
37. Sandeep TC, Andrew R, Homer NZ, Andrews RC, Smith K, Walker BR 2005 Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 54:872-879
38. Rask E, Olsson T, Söderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421
39. Rask E, Walker BR, Söderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T 2002 Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336
40. Wake DJ, Rask E, Livingstone DE, Söderberg S, Olsson T, Walker BR 2003 Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 88:3983-3988
41. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, Walker BR 2003 Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposityandinsulinemia in PimaIndians and Caucasians. J Clin Endocrinol Metab 88:2738-2744
42. Kannisto K, Pietiläinen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, Yki-Järvinen H 2004 Overexpression of 11β- hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 89:4414-4421
43. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM 2002 Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 87:5630-5635
44. Michailidou Z, Jensen MD, Dumesic DA, Chapman KE, Seckl JR, Walker BR, Morton NM 2007 Omental 11β-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 15:1155-1163
45. Lee MJ, Fried SK, Mundt SS, Wang Y, Sullivan S, Stefanni A, Daugherty BL, Hermanowski-Vosatka A 2008 Depot-specific regulation of the conversion of cortisone to cortisol in human adipose tissue. Obesity (Silver Spring) 16:1178-1185
46. Veilleux A, Rheaume C, Daris M, Luu-The V, Tchernof A 2009 Omental adipose tissue 11β-HSD1 oxoreductase activity, body fat distribution and metabolic alterations in women. J Clin Endocrinol Metab 94:3550-3557
47. Morton NM, Seckl JR 2008 11β-Hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 36:146-164
48. Stimson RH, Johnstone AM, Homer NZ, Wake DJ, Morton NM, Andrew R, Lobley GE, Walker BR 2007 Dietary macronutrient content alters cortisol metabolism independently of body weight changes in obese men. J Clin Endocrinol Metab 92:4480-4484
49. Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM 2008 Impaired glucose tolerance and insulin resistance are associated with increased adipose 11β-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5α-reductase activity. Diabetes 57:2652-2660
50. Ishii T, Masuzaki H, Tanaka T, Arai N, Yasue S, Kobayashi N, Tomita T, Noguchi M, Fujikura J, Ebihara K, Hosoda K, Nakao K 2007 Augmentation of 11β-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages - role of 11β-HSD1 in pro-inflammatory properties in macrophages. FEBS Lett 581:349-354
51. Morton NM, Ramage L, Seckl JR 2004 Down-regulation of adipose 11β-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145:2707-2712
52. Morton NM, Densmore V, Wamil M, Ramage L, Nichol K, Bünger L, Seckl JR, Kenyon CJ 2005 A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action. Diabetes 54:3371-3378
53. Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L, Stewart PM 2004 Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J Clin Endocrinol Metab 89:2711-2716
54. Drake AJ, Livingstone DE, Andrew R, Seckl JR, Morton NM, Walker BR 2005 Reduced adipose glucocorticoid reactivation and increased hepatic glucocorticoid clearance as an early adaptation to high-fat feeding in Wistar rats. Endocrinology 146:913-919
55. Andrews RC, Walker BR 1999 Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Colch) 96:513-523
56. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, Kumar S 2004 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 89:4755-4761
57. Morton NM, Holmes MC, Fiévet C, Staels B, Tailleux A, Mullins JJ, Seckl JR 2001 Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:41293-41300
58. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingström G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Björkstrand E, Abrahmsen LB 2003 Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762
59. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R 2005 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517-527
60. Rosenstock J, Banarer S, Fonseca V, Inzucchi S, Hollis G, Flores R, Levy R, Williams B, Huber R Efficacy and safety of the 11-β-HSD1 inhibitor, INCB13739, added to metformin therapy in patients with type 2 diabetes. Proc 69th Scientific Sessions Meeting of the American Diabetes Association, New Orleans 2009 p.LB3 (Abstract 7-LB)
61. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone-〉cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027
62. Westerbacka J, Yki-Järvinen H, Vehkavaara S, Häkkinen AM, Andrew R, Wake DJ, Seckl JR, Walker BR 2003 Body fat distribution and cortisol metabolism in healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88:4924-4931
63. Basu R, Basu A, Grudzien M, Jung P, Jacobson P, Johnson M, Singh R, Sarr M, Rizza RA 2009 Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 58:39-45
64. Stimson RH, Andersson J, Andrew R, Redhead DN, Karpe F, Hayes PC, Olsson T, Walker BR 2009 Cortisol release from adipose tissue by 11β-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 58:46-53
65. Whorwood CB, Donovan SJ, Wood PJ, Phillips DI 2001 Regulation of glucocorticoid receptor α and β isoforms and type I 11β-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab 86:2296-2308
66. Zhang M, Lv XY, Li J, Xu ZG, Chen L 2009 Alteration of 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes. Mol Cell Biochem 324:147-155
67. Davani B, Khan A, Hult M, Mårtensson E, Okret S, Efendic S, Jörnvall H, Oppermann UC 2000 Type 1 11β-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 275:34841-34844
68. Swali A, Walker EA, Lavery GG, Tomlinson JW, Stewart PM 2008 11β-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia 51:2003-2011
69. Walker BR, Yau JL, Brett LP, Seckl JR, Monder C, Williams BC, Edwards CR 1991 11β-Hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology 129:3305-3312
70. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR 2003 11β-Hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 42:580-587
71. Dover AR, Hadoke PW, Macdonald LJ, Miller E, Newby DE, Walker BR 2007 Intravascular glucocorticoid metabolism during inflammation and injury in mice. Endocrinology 148:166-172
72. Hult M, Elleby B, Shafqat N, Svensson S, Rane A, Jörnvall H, Abrahmsen L, Oppermann U 2004 Human and rodent type 1 11β- hydroxysteroid dehydrogenases are 7β-hydroxycholesterol dehydrogenases involved in oxysterol metabolism. Cell Mol Life Sci 61:992-999
73. Schweizer RA, Zürcher M, Balazs Z, Dick B, Odermatt A 2004 Rapid hepatic metabolism of 7-ketocholesterol by 11β-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, and hamster enzyme. J Biol Chem 279:18415-18424
74. Wamil M, Andrew R, Chapman KE, Street J, Morton NM, Seckl JR 2008 7-Oxysterols modulate glucocorticoid activity in adipocytes through competition for 11β-hydroxysteroid dehydrogenase type. Endocrinology 149:5909-5918
75. Rhen T, Cidlowski JA 2005 Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 353:1711-1723
76. Hardy R, Cooper MS 2009 Bone loss in inflammatory disorders. J Endocrinol 201:309-320
77. Cooper MS, Stewart PM 2003 Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348:727-734
78. Chapman KE, Coutinho AE, Gray M, Gilmour JS, Savill JS, Seckl JR 2009 The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 301:123-131
79. Freeman L, Hewison M, Hughes SV, Evans KN, Hardie D, Means TK, Chakraverty R 2005 Expression of 11β-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells. Blood 106:2042-2049
80. Gilmour JS, Coutinho AE, Cailhier JF, Man TY, Clay M, Thomas G, Harris HJ, Mullins JJ, Seckl JR, Savill JS, Chapman KE 2006 Local amplification of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 176:7605-7611
81. Schmidt M, Weidler C, Naumann H, Anders S, Schölmerich J, Straub RH 2005 Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum 52:1711-1720
82. Haas CS, Creighton CJ, Pi X, Maine I, Koch AE, Haines GK, Ling S, Chinnaiyan AM, Holoshitz J 2006 Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 54:2047-2060
83. Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, Aune TM 2004 A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis 63:1387-1392
84. Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, Gittoes NJ, Buckley CD, Raza K, Cooper MS 2008 Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 67:1204-1210
85. Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, van Denderen JC, Westedt ML, Peeters AJ, Dijkmans BA, Jacobs P, Boonen A, van der Heijde DM, van Der Linden S 2002 COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 46:347-356
86. Zhang TY, Ding X, Daynes RA 2005 The expression of 11β-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities. J Immunol 174:879-889
87. Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM 2002 Osteoblastic 11β-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Miner Res 17:979-986
88. D'Elia M, Patenaude J, Bernier J 2009 Regulation of glucocorticoid sensitivity in thymocytes from burn-injured mice. Am J Physiol Endocrinol Metab 296:E97-E104
89. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ 1997 Tumor necrosis factor-α and interleukin-1β enhance the cortisone/cortisol shuttle. J Exp Med 186:189-198
90. Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM 2001 Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16:1037-1044
91. Yong PY, Harlow C, Thong KJ, Hillier SG 2002 Regulation of 11β-hydroxysteroid dehydrogenase type 1 gene expression in human ovarian surface epithelial cells by interleukin-1. Hum Reprod 17:2300-2306
92. Bryndová J, Zbánková S, Kment M, Pácha J 2004 Colitis up-regulates local glucocorticoid activation and down-regulates inactivation in colonic tissue. Scand J Gastroenterol 39:549-553
93. Kaur K, Hardy R, Ahasan MM, Eijken M, van Leeuwen JP, Filer A, Thomas AM, Raza K, Buckley CD, Stewart PM, Rabbitt EH, Hewison M, Cooper MS 2009 Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss. Ann Rheum Dis, DOI:10.1136/ard.2009.107466
94. Webster SP, Ward P, Binnie M, Craigie E, McConnell KM, Sooy K, Vinter A, Seckl JR, Walker BR 2007 Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors. Bioorg Med Chem Lett 17:2838-2843
95. Bujalska IJ, Gathercole LL, Tomlinson JW, Darimont C, Ermolieff J, Fanjul AN, Rejto PA, Stewart PM 2008 A novel selective 11β- hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol 197:297-307
96. Boyle CD, Kowalski TJ 2009 11β-Hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents. Expert Opin Ther Pat 19:801-825
97. Sahni-Arya B, Flynn MJ, Bergeron L, Salyan ME, Pedicord DL, Golla R, Ma Z, Wang H, Seethala R, Wu SC, Li JJ, Nayeem A, Gates C, Hamann LG, Gordon DA, Blat Y 2007 Cofactor-specific modulation of 11β-hydroxysteroid dehydrogenase 1 inhibitor potency. Biochim Biophys Acta 1774:1184-1191
98. Tu H, Powers JP, Liu J, Ursu S, Sudom A, Yan X, Xu H, Meininger D, Degraffenreid M, He X, Jaen JC, Sun D, Labelle M, Yamamoto H, Shan B, Walker NP, Wang Z 2008 Distinctive molecular inhibition mechanisms for selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem 16:8922-8931
99. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR 2004 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 101:6734-6739